Talazoparib tosylate (BMN 673ts) is a potent, orally bioavailable small molecule inhibitor of PARP1 and PARP2. It is widely used in preclinical research, including in vitro cell-based assays and in vivo xenograft models, to investigate targeted therapies for BRCA-mutated breast and ovarian cancers.